Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 6 institutions in 1 country.
Yanhong LiuDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-6747-6834
Jennifer R KramerDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-2953-4949
Vlad C SandulacheENT Section, Operative Care Line, Michael E. DeBakey VA Medical Center, Houston, Texas.ORCID 0000-0002-9205-385X
Robert YuDepartment of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1549-7115
Guojun LiDepartment of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9505-1502
Liang ChenDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-7395-3759
Zenab I YusufDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-5384-8855
Yunling ShiCenter for Data and Computational Sciences, VA Boston Healthcare System, Boston, Massachusetts.ORCID 0000-0002-3830-8866
Saiju PyarajanCenter for Data and Computational Sciences, VA Boston Healthcare System, Boston, Massachusetts.ORCID 0000-0002-9047-3762
Spyros TsavachidisDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-9287-4818
Michelle L MierzwaUniversity Hospital, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-3923-9970
Elizabeth ChiaoDepartments of Epidemiology and General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5752-2916
Yvonne M MoweryDepartments of Radiation Oncology and Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-9839-2414
Andrew ShumanDepartment of Otolaryngology, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0002-9305-7860
Sanjay SheteDepartment of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7622-376X
Andrew G SikoraDepartment of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8357-8435
Donna L WhiteDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-0297-2949
Michael E. DeBakey VA Medical Center · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Michigan · USVA Boston Healthcare System · USDuke University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancerU01DE028233 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANNAPRAGADA, ANANTH V, SIKORA, ANDREW · 2018 to 2022
$3.9M
Genome Wide Association Study of Head and Neck CancerR01CA131324 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHETE, SANJAY · 2009 to 2013
$2.8M
Immuno-inflammatory Response Non-coding RNAs as Predictors of HPV Status & Outcome of Oropharyngeal Cancer PatientsR01CA236859 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2020 to 2024
$1.5M
Employing Novel Primary Mouse Models of Head and Neck Cancer to Overcome Chemoradiation ResistanceK08DE029887 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOWERY, YVONNE MARIE · 2020 to 2024
$804k
Evaluating Etiological Impact of Metatranscriptomic and Immunological Features for Lung CancerR03CA262911 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIU, YANHONG · 2021 to 2022
$160k
Sex hormones and HCV-related liver disease progressionI01CX001430 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI WHITE, DONNA LORRAINE · 2017 to 2021
Increasing rates of human papillomavirus (HPV)-driven oropharyngeal cancer (OPC) have largely offset declines in tobacco-associated head and neck squamous cell carcinoma (HNSCC) at non-OPC sites. Host immunity is an important modulator of HPV infection, persistence, and clearance, and also of immune evasion in both virally- and nonvirally-driven cancers. However, the association between collective known cancer-related immune gene variants and HNSCC susceptibility has not been fully characterized. Here, we conducted a genetic association study in the multiethnic Veterans Affairs Million Veteran Program cohort, evaluating 16,050 variants in 1,576 immune genes in 4,012 HNSCC cases (OPC = 1,823; non-OPC = 2,189) and 16,048 matched controls. Significant polymorphisms were further examined in a non-Hispanic white (NHW) validation cohort (OPC = 1,206; non-OPC = 955; controls = 4,507). For overall HNSCC susceptibility in NHWs, we discovered and validated a novel 9q31.1 SMC2 association and replicated the known 6p21.32 HLA-DQ-DR association. Six loci/genes for overall HNSCC susceptibility were selectively enriched in African-Americans (6p21.32 HLA-G, 9q21.33 GAS1, 11q12.2 CD6, 11q23.2 NCAM1/CD56, 17p13.1 CD68, 18q22.2 SOCS6); all 6 genes function in antigen-presenting regulation and T-cell activation. Two additional loci (10q26 DMBT1, 15q22.2 TPM1) were uncovered for non-OPC susceptibility, and three loci (11q24 CRTAM, 16q21 CDH5, 18q12.1 CDH2) were identified for HPV-positive OPC susceptibility. This study underscores the role of immune gene variants in modulating susceptibility for both HPV-driven and non-HPV-driven HNSCC. Additional large studies, particularly in racially diverse populations, are needed to further validate the associations and to help elucidate other potential immune factors and mechanisms that may underlie HNSCC risk. SIGNIFICANCE: Several inherited variations in immune system genes are significantly associated with susceptibility to head and neck cancer, which could help improve personalized cancer risk estimates.
Indexed as
Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsVeteransCalcium-Binding ProteinsDNA-Binding ProteinsHuman Papillomavirus VirusesHumansImmunogeneticsSquamous Cell Carcinoma of Head and NeckSuppressor of Cytokine Signaling ProteinsTumor Suppressor ProteinsCalcium-Binding ProteinsDMBT1 protein, humanDNA-Binding ProteinsSOCS6 protein, humanSuppressor of Cytokine Signaling ProteinsTumor Suppressor Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort. · full record | OpenQuestion